Moving toward the next level in breast cancer CAR T cell therapy
October 31, 2019 | By City of Hope
City of Hope is accelerating the development of treatment options for patients with breast cancer who have challenging tumors and poor prognosis with a phase 1 clinical trial that is enrolling patients with refractory HER2-positive breast cancer with brain metastases to test the safety and effectiveness of CAR T cell therapy.
City of Hope is accelerating the development of treatment options for patients with breast cancer who have challenging tumors and poor prognosis with a phase 1 clinical trial that is enrolling patients with refractory HER2-positive breast cancer with brain metastases to test the safety and effective
Despite the availability of many emerging treatments for multiple myeloma, it remains an incurable cancer. As a pioneer in advancing personalized medicine and commitment to improved patient outcomes, City of Hope experts have joined efforts for a unique clinical trial.
Stacy Gray, M.D., associate clinical professor in the Division of Clinical Cancer Genomics, is one of six physicians to receive an inaugural “Genomic Innovator Award” from the National Human Genome Institute (NHGI).
City of Hope is the first institution in the United States to open an immunotherapy clinical trial for liver cancer that eventually could transform treatment of the usually fatal disease into an outpatient procedure.
In this phase 1 trial, the safety and tolerability of autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes are studied in adult patients with PSCA+ metastatic castration-resistant prostate cancer.
City of Hope has the clinical and scientific expertise to house the entire clinical trial process on its campus — including collecting the cells, manufacturing the lentivirus, modifying and replicating the cells and reinfusing them.
A cure for Type 1 diabetes (T1D) in six years is the new goal of City of Hope’s Diabetes and Metabolism Research Institute. With more than $50 million in private funding, the institute will be able to lead an innovative research effort that seeks to find a cure for T1D.
One of but a few centers in the United States offering human studies in CAR–T cell therapy, City of Hope is the only center investigating CAR T cells in injection form administered directly to brain tumors.
In this Q and A, Steven T. Rosen, M.D., provost and chief scientific officer for City of Hope, answers questions about the importance of precision medicine in the fight against cancer and how the City of Hope and TGen alliance will advance research and treatment using this approach.
As cancer survival rates in the United States increase due to improving detection and treatment protocols, a growing number of patients are faced with a new and difficult challenge - living with chronic pain. Interventional pain medicine, a new specialty that draws from several branches of medicine,
Bart Roep, M.D., Ph.D., chair of City of Hope’s Department of Diabetes Immunology and an internationally recognized immunologist, is leading a clinical trial that just might lead to a cure for type 1 diabetes.